An evaluation of a commercial TLC Kit System (Toxi-Lab'") is described. The performance of the system is assessed in the detection of drugs in overdose and in therapy, and is compared with a GC drug screening system.
Introduction
Deliberate ingestion of poisons and overdoses of drugs account for about 10% of the total acute medical admissions to hospital and, in an increasing number of such cases, the laboratory is asked to perform a 'drug screen'. Drug screening is clinically most useful in assessing the need for treatment in acutely poisoned patients who may have serious complications, and in seriously ill patients not responding to conventional medical therapy and in whom poisoning is thought to be a possible cause. It is important in non-accidental poisoning as with child abuse, in prolonged coma and suspected brain death and in the diagnosis of drug abuse.
The range of toxic substances taken in acute poisoning is very large and identification is further complicated by the fact that about 50% of poisoned patients have ingested more than one toxic substance. Because of the complexity of the mixtures of drugs that can be present in body fluids, chromatographic techniques are particularly useful for drug screening. Thinlayer chromatography (TLC) is one of the most widely used techniques for the separation and identification of toxic substances in biological fluids. We describe the evaluation of a commercially available TLC kit system, the Toxi-Lab'P System (Analytical Systems Inc, Laguna Hills, 76 California, USA).1-3 This system has been standardised to reduce the variability inherent in most TLC procedures. There are two extraction and chromatography systems. Toxi-Lab A (System A) is designed for the identification of basic and neutral drugs (eg, analgesics, stimulants and tranquillisers). Analyses on urine are to be preferred, but this system can also be applied to gastric aspirate if this is available. Serum concentrations of these drugs are generally too low to permit reliable detection. Toxi-Lab B (System B) is designed for the identification of acidic and neutral drugs; the staining procedure is particularly designed to detect barbiturates, benzodiazepines and some other non-barbiturate hypnotics.
Unknown spots are identified by reference to a compendium which contains a card index of photographs showing chromatograms arranged in order of R, value with an alphabetical index and a large amount of other information relating to the 127 compounds presently included. Most of the chromatograms are of drugs and their metabolites in urine: processed by System A. Very few System B examples are included. Unknown drugs are identified by position (R, value), colour of the spots after every dip, and metabolite pattern. The depiction of metabolite patterns makes the system ideal for the identification of drugs in urine.
Results obtained by the application of the Toxi-Lab systems to samples of urine and plasma were compared with information obtained from the patient, relatives, etc, and with results of a dual-column gas chromatographic (GC) procedure." In a number of cases plasma drug concentrations were measured by high performance liquid chromatography (HPLC) or. by specific GC methods.
Materials and methods

PATIENTS' SPECIMENS
Two groups of poisoned patients were investigated. The first series (31 patients) was admitted to the Regional Poisoning Treatment Centre, Royal Infirmary of Edinburgh, mostly with tricyclic antidepressant overdose, between March 1980 and August 1981. The second series (101 patients) was admitted with a variety of drug overdoses between November 1982 and August 1984. Samples were taken for analysis as soon as possible after admission; in the majority of cases urine and blood samples were available. Urine was collected into 25 mL plastic containers, blood into 10 mL plastic tubes with lithium heparin as anticoagulant.
Urine samples were also obtained from a group of psychiatric patients at the Metabolic Unit, Royal Edinburgh Hospital. There were 27 patients receiving therapeutic doses of drugs and 22 patients who had not taken any drugs (apart from lithium carbonate) during the preceding 5 days.
For the assessment of benzodiazepine screening, plasma samples from both series of poisoned patients were used, and plasma from 14 other patients from whom no urine specimens were received.
TOXI-LAB SCREENING
Toxi-Lab kits were obtained from the manufacturers' agents, Mercia Diagnostics Ltd, Weybridge, UK. The kit includes stoppered tubes containing a mixture of solvents and buffering salts for the extraction of basic and neutral drugs (System A) or acidic and neutral drugs (System B), and special chromatograms made of glass microfibre and silica gel (approximately 4 x 11 ern). Four standard discs are preinserted in the chromatograms which also have two spare holes for insertion of small discs of chromatographic medium on to which the unknown substances are deposited.
Samples of urine (5 mL) or plasma (2 mL
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plus 2·5 mL water) were added to the tubes, and drugs and metabolites were extracted by inversion. The solvent extracts were concentrated on to discs by evaporation and the dried discs inserted into the spare holes on the pre-standardised chromatograms. In System A analysis, two unknown discs were inserted: five drops of extract were evaporated on to the right-hand disc and the remainder on to the left-hand disc. After development of the chromatograms, detection of the unknown and standard drug spots was achieved by sequentially dipping the chromatograms in a series of reagents and recording the position and colour of the spots at each stage on a worksheet supplied by the manufacturer. The compendium was used to identify drugs and metabolites present. Confirmation of the presence of morphine was achieved by detection with silver nitrate and differentiation of amphetamines by remigration in acetone as directed by the manufacturers. Technical details are as follows: Extraction tubes (A) contain sodium carbonate and bicarbonate to give a pH of 9·0, and a mixture of dichloromethane and dichloroethane. Extraction tubes (B) contain zinc chloride (to give pH 4,5) and dichloromethane.
Developing solvents are (A) methanolwater-ethyl acetate (2: 1:58) and (B) chloroform-ethyl acetate (60:40). To 3 mL of each solvent is added immediately before development the volume of ammonia solution (SG 0·880) specified on the batch of chromatograms (usually 15-20 I-tL). Stage II: visualisation under ultraviolet light (wavelength 366 nm).
Location reagents (AJ
GAS CHROMATOGRAPHY (GC) SCREENING
The dual-column GC method used for screen-ing the first series of poisoned patients consisted of a Perkin-Elmer Sigma 3B system with an OV-17 column linked to a nitrogenphosphorus detector and an OV-275 column with a flame-ionisation detector. Details of the operation of this system and its application to drug screening have been described previously." This system was subsequently modified and improved by the replacement of the OV-275 column and flame-ionisation detector by a CP Wax 4000 column with a nitrogenphosphorus detector.
CONFIRMATORY METHODS
Specific confirmatory methods for tricyclic antidepressants in plasma by HPLC, and for benzodiazepines and barbiturates in plasma by GC, have been described previously."
Results
PERFORMANCE OF THE IDENTIFICATION
PROCEDURES
Use of the compendium is the method of choice for the identification of unknown drugs. In the present study, however, only 35 of the 65 drugs suspected on circumstantial and clinical grounds were listed in the compendium; of these 19 were confirmed using the compendium.
Additional information on 52 non-compendium drugs was received from the manufacturers' agent. This was in the form of a series of Toxi-Lab worksheets on which the drug spot had been drawn and coloured by hand. With six exceptions this information related to the parent drug only. Twelve of the suspected drugs fell into this category; four of these were confirmed using this information.
When no information was available from the manufacturers, standard chromatograms of the pure drugs were prepared locally using 10 mg/L solutions in distilled water, which were extracted according to the standard procedure for urine (System A or B). Seventeen of the suspected drugs fell into this category; four of these were confirmed in this way.
PERFORMANCE IN THE INVESTIGATION OF POISONED PATIENTS
Urine analysis by System A performed reasonably well in the confirmation of drugs suspected to have been taken (Table 1) ; suspected drugs were confirmed in 58% of cases. Furthermore, in 24% of cases, drugs were identified which had not hitherto been suspected. Nicotine was detected in 32% of cases; this could be a disadvantage where it or its metabolite masked other drug spots. Caffeine was detected in 16% of cases but was easily recognised. In 36% of cases, significant unidentified material was seen. In only 5% of samples were no abnormalities detected (other than caffeine and nicotine).
Urine did not prove a useful medium for System B: in only six out of 31 urines tested was significant staining detected. Plasma proved more successful, particularly for the detection A total of 65 different drugs were suspected to have been taken by the population of patients studied; some were multiple overdoses. Table 2 lists the 32 drugs most commonly suspected. Sometimes, groups of compounds such as 'opiates' or 'amphetamines' were suspected;
LJrug screening 79 phenothiazines have also been grouped together since they are difficult to distinguish from each other by Taxi-Lab. Many of these drugs were successfully detected in urine by System A. System A performed well in the confirmation of tricyclic antidepressant poisoning; these drugs are frequently taken in overdose and can cause serious clinical problems. Further confirmation was established by measuring amitriptyline and imipramine in the plasma of 27 patients by HPLC (Table 3 ). Urine samples were positive for tricyclic antidepressants by System A in all but four cases: two of these had therapeutic plasma amitriptyline concentrations but two had toxic plasma amitriptyline concen- trations (700 and 1890 IJ.g/L respectively) and were presumably not excreting significant amounts of the drug and metabolites into the urine. No explanation has been found for this phenomenon; the urine samples were not collected particularly early after the overdose. Benzodiazepines appear in urine largely in the form of non-extractable conjugates. Acid hydrolysis of these is recommended by the manufacturers for the confirmation of benzodiazepines. Detection of the resulting benzophenones by Toxi-Lab is sensitive, but different benzodiazepines are not usually distinguished from each other and some (eg, nitrazepam and flurazepam) are not visualised at all. The procedure is time-consuming and represents an added expense. The unhydrolysed benzodiazepine conjugates are poorly detected in urine by System A, with the stated exception of temazepam and flurazepam whose metabolic patterns are included in the compendium. In our hands, however, this procedure was not very effective at detecting temazepam and flurazepam metabolites in urine from the 15 patients who had taken these drugs.
Plasma contains the unconjugated benzodiazepines, which can be detected by System B. The sensitivity of this technique was investigated by measuring benzodiazepines in the plasma of 73 poisoned patients by electroncapture GC (Table 3) . 4 Toxic concentrations of the commonly found drugs diazepam, des-methyldiazepam, temazepam and desalkylflurazepam were readily confirmed in the plasma by System B. Desmethyldiazepam is frequently found in the same plasma as diazepam, of which it is a metabolite. Diazepam could be easily identified, being the only benzodiazepine whose fluorescence matched that of the diazepam standard. However, desmethyldiazepam, temazepam and desalkylflurazepam could not be easily distinguished from each other on the basis of R, value or staining pattern. Nitrazepam was less readily detected; it is not fluorescent and could be mistaken for a barbiturate. Lorazepam was not detected in any of the three patients who had ingested it. Of the other benzodiazepines analysed, only oxazepam (1890 IJ.g/L) in one plasma specimen was detectable by System B. Bromazepam, clobazam and chlordiazepoxide were not detected in plasma samples in which positive GC results (qualitative) were obtained. Of the 25 plasma samples in which no benzodiazepines were detected by GC, three showed fluorescent spots and two showed purple spots; none corresponded in position to the benzodiazepines. The remaining 20 samples showed no abnormalities.
Barbiturates are not usually visualised by System A, since their extraction and staining is poor. System B was very sensitive to barbiturates, however; low therapeutic concentrations were readily confirmed in plasma.
Polyethylene glycol was detected by System
A in urine samples from four patients suspected of taking temazepam or nifedipine. This derives from the ingestion of liquid preparations of these drugs in gelatin capsules and may mask other more specific drug spots. Salicylate was detected in only one of five patients suspected to have taken it; however, Toxi-Lab is not very sensitive to salicylate (sensitivity approximately 100 mg/L in urine) and it no longer appears in the compendium. COMPARISON WITH GAS CHROMATOGRAPHIC SCREENING Gas chromatographic screening of urine" in general yielded less information than Toxi-Lab. Its application to the investigation of poisoned patients is shown in Table 1 . Total numbers differ from those for Taxi-Lab since, in cases where material was limited, urines were used preferentially for Taxi-Lab and plasma samples for Gc. Urine screening by GC was rather less effective than Toxi-Lab in confirming the nature of drugs suspected, and in the identification of unsuspected drugs. Unidentified peaks, presumably drug metabolites in many cases, were seen in 93% of urines screened by GC and could complicate the analysis. The nitrogen detector was very sensitive to caffeine; nicotine on the other hand never interfered owing to its short retention time and its volatility, which can lead to its loss at the drying-down stage. The performance of plasma in GC screening was rather less effective than that of urine. More suspected drugs were confirmed in plasma by GC than by Taxi-Lab B due to the restricted range of Taxi-Lab B.
In the confirmation of poisoning by specific drugs ( Table 2) , GC urine screening performed Drug screening 81 slightly better than Taxi-Lab in two (amitriptyline and flurazepam) of the 32 drugs listed. In 10 cases Toxi-Lab was more effective than GC; in six cases there was little significant difference; and 14 drugs were not confirmed in any urine by either method. However, it must be stressed that many poisoned patients may not have taken the drug they claim to have taken. Plasma screening by GC again proved less effective than urine screening, with the sole exception of diazepam which was confirmed in three plasma samples by Gc.
Lignocaine was detected in several samples, both by Toxi-Lab and by Gc. This drug is often used as a local anaesthetic in intubation and catheterisation, information that is frequently not provided to the laboratory by the requesting clinician. In the latter case lignocaine alone appears in the urine; if lignocaine has been ingested, metabolites are also detected.
PERFORMANCE IN COMPLIANCE
MONITORING
Drug compliance is a major problem in psychiatric units. Of 27 patients on therapeutic doses of drugs, only four were confirmed in urine by System A ( Table 4 ). Thirteen other patients showed some unidentified staining; this was usually minimal but in four cases definite spots were seen. Chloral hydrate metabolites were detected by the Fujiwara reaction in urine from the patient taking it; amylobarbitone is best detected in therapeutic amounts in plasma by System B. In contrast, only three out of 22 supposedly drug-free patients showed any staining at all; one of these was strongly positive for phenothiazine metabolites and was presumably taking a drug of this group. Disulfiram compliance is a particular problem in alcoholic patients; the two urines tested were positive for disulfiram metabolites by the method of Neiderhiser et al? However, the drug was not detected in the urine by System A, either by the standard technique or by migration in the alternative solvent recommended by the manufacturers, dichloromethane:heptane (2:1 by volume).
Discussion
The Toxi-Lab A and B systems provide a drug screening method that can be used to determine the presence or absence of many clinically important drugs and metabolites. Basic TLC procedures have been simplified and the method is easy to use and fairly rapid, requiring about 60 min to perform the A and B screens.
The major problems of sample application, standardisation and interpretation in conventional TLC have been greatly reduced in the Toxi-Lab system. The disc insertion procedure maintains a reproducible spot size. Chromatograms are already provided with calibration standards against which the migration of unknown compounds may be assessed. Identification is aided by the compendium which provides a visual record of the patterns observed for drugs and metabolites and represents accurately the colours of the spots. Location reagents are applied by a dipping technique which is safer than spraying, especially for reagents containing organic solvent or concentrated acid. Extraction procedures have been standardised.
Some problems in drug detection by conventional TLC also affect the Toxi-Lab systems: (1) the concentration may be too low, resulting in equivocal staining and indistinct colours-colour and R, values of spots may both vary with concentration, making recognition difficult; (2) drugs migrating with very high or very low R, values are difficult to distinguish from recognised artifacts; (3) the drug may not stain well, leading to poor sensitivity; (4) spots may be masked by other drugs or metabolites-some of the patterns obtained in multiple overdose may be difficult to interpret; (5) the drug may be present in plasma but poorly extracted into urine (as in the case of the two amitriptyline overdoses reported); (6) the metabolites may be too polar to extract (eg, urinary benzodiazepine conjugates).
The compendium is an effective reference for drug identification, because it depicts the metabolite patterns in human urine. The systems were developed in the USA, however, and were originally designed for the detection of drugs widely used in that country, with the consequence that many common UK drugs (eg nitrazepam, mianserin, dipipanone) are omitted from the compendium. As a result, many unknown spots are observed which cannot be identified from the compendium. In addition, the range of drugs covered by the System B chromatograms is very restricted. It is to be hoped that the manufacturers will extend the information to cover all drugs commonly available in the UK so that the compendium can be used with greater confidence and success in this country.
An attempt was made to identify drugs not listed in the compendium by using chromatograms prepared from pure standards, either locally or by the manufacturer's agent. Neither was particularly successful; both suffered from the lack of metabolite data. The metabolite spots are frequently more prominent than those of the parent drug on urine chromatograms. It is possible for laboratories to compile their own libraries of metabolite patterns for a few non-compendium drugs. This is only feasible when the drug has a distinctive metabolite pattern, and has been taken in significant amounts by several patients, preferably not in combination with other drugs. Mianserin and dothiepin have been characterised in this way in this labortory.
Identification of drugs and metabolites using the compendium requires some experience and skill in interpretation; this important step in the procedure is facilitated by attending a training course and periodical workshops organised by the manufacturers' agent. Further experience and an assessment of the analyst's performance can be obtained by participation in the manufacturers' proficiency testing scheme.
In this study, Toxi-Lab analysis proved more successful than GC analysis in the investigation of poisoning because metabolite patterns are known in many cases and identification depends on colour as well as position of spots. One important aspect was the detection of unsuspected drugs in a significant number of samples by the Toxi-Lab system. The GC system was much less successful in this respect and even drugs suspected by the clinicians were less readily confirmed by GC than by Toxi-Lab.
The use of GC for drug screening is limited by the lack of specificity of the commonly used detectors and by the fact that identification relies on building up a library of retention times of drugs and metabolites run through the system. When linked to a mass selective detector, GC can provide a very sensitive and highly specific method of identification of unknown drugs and rnetabolites'r" but GC-mass spectrometer systems are not available in most hospital laboratories.
In our experience, the Toxi-Lab systems were of limited value for the detection and identification of benzodiazepines. Un hydrolysed conjugates were poorly detected in urine by System A. Hydrolysis of conjugates, as recommended by the manufacturers, did lead to an improvement in detection but there were still problems in identification of the parent benzodiazepine. The unconjugated forms of certain benzodiazepines, eg, diazepam, were readily detected in plasma by System B but other members of this group, eg, nitrazepam and lorazepam, were less easily detected.
Drug screening is sometimes requested, particularly by psychiatrists, to check the compliance of patients taking prescribed medication. Bury and Mashford" reported that 'the Toxi-Lab system was capable of detecting most drugs and metabolites in urine after ingestion of therapeutic amounts. In contrast, this study shows that the System A urine screen is insufficiently sensitive for the detection of therapeutic amounts of psychoactive drugs. This screen must be used, therefore, with caution likewise in the assessment of patients with suspected brain death from whom Iifesupport systems may be about to be withdrawn.
Screening for drugs of abuse is an increasingly important function of the toxicology laboratory. Toxi-Lab A has proved useful in the screening of urine from drug addicts in a large local practice and in the local psychiatric hospital. It has proved effective at detecting most of the drugs frequently encountered; exceptions are buprenorphine and dipipanone. This technique has an advantage over the widely-used immunoassay procedures in that many drugs are screened for in a single analysis. The manufacturers have recently introduced into the UK a kit for the detection of cannabinoids,
Cost is an important factor to be considered in the application of this simplified TLC procedure, particularly if any of the confirmatory chromatographic tests are required. For screening by one system (A or B) , the cost based on reagents and consumables is about £3·80 per sample. The compendium, costing £406, is an Drug screening 83 essential component of the Toxi-Lab system. It currently contains information relating to 127 compounds and is updated twice yearly. The first two updates are included in the initial price of the system; thereafter, two updates cost £75. Participation in the manufacturer's proficiency testing service at a cost of £100 per annum is desirable. The comparatively high running costs may mean that the use of this system must be restricted, or at least, carefully controlled. In this department, all requests for Toxi-Lab screens, as for other requests for drug screening, are discussed with the clinical staff before the analysis is performed. The most efficient screen in terms of the information generated is System A analysis of urine. The major groups of compounds which are not detected by System A are the barbiturates and the benzodiazepines. These are detected by System B; the latter, with reservations, only in plasma. The most effective use of the procedure is, therefore, in the screening of urine by System A and plasma by System B; there will be many cases in which only the A screen is indicated (eg, in suspected opiate or amphetamine abuse). System A may alternatively be performed on gastric aspirate; this may be more sensitive for orally-ingested drugs where these are still present in the stomach, but the characteristic metabolite pattern will not be seen.
The role of the Toxi-Lab system in a laboratory will depend on the frequency and pattern of drug screening requests and the methods currently available for this purpose. The system appears to be ideally suited to the small laboratory which is required to perform the occasional toxicology screen, or where there is a specific need such as drug abuse screening. By comparison with a simple UV urine screening method, the Toxi-Lab system is neither more time-consuming nor more difficult to perform and it is much more informative; it is, however, more expensive. In large laboratories, where the expertise exists, Toxi-Lab can be backed up by GC screening to provide confirmation of identity, and to help in those cases where the drug is difficult to visualise by Toxi-Lab, or where no urine sample can be obtained.
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